Immunological and Histological Evaluation of Specific Immunotherapy With Recombinant Hypoallergenic Derivative

Phase 2 Completed 14 enrolled Allergopharma GmbH & Co. KG

RandomizedParallel-groupQuadruple-blindBasic science

Summary

This trial is performed for the immunological and histological evaluation of specific immunotherapy with an aluminium hydroxide-adsorbed recombinant hypoallergenic derivative of the major birch pollen allergen, rBet v1-FV

Timeline

Start: 2007-12
Primary completion: 2011-04
Completion: 2013-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	rBet v1-FV	Protein / enzyme biologic	80 ug	Subcutaneous

Immunological and Histological Evaluation of Specific Immunotherapy With Recombinant Hypoallergenic Derivative

Summary

Timeline

Drugs

Indications